Adamis Pharmaceuticals (ADMP) Improves Its IP

Adamis Pharmaceuticals (ADMP) issued a press release prior to the market opening yesterday (2014.01.24) that I thought was good news. The press release started with the following.

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced an important addition to its intellectual property with receipt of a Notice of Allowance of patent claims supporting its cancer immunotherapy portfolio in the United States. Notice of Allowance is the final step in the issuance of a patent. The company believes that this patent will significantly strengthen Adamis' cancer immunotherapy patent portfolio and will further support its TeloB-VAX vaccine technology.

ADMP had a gap opening yesterday (02014.01.24) at $7.02 (previous close was $6.80). It spiked to $7.25 before falling to a close of $6.68 (down almost 2% for the day). Volume was 6-time trailing-3-month average. 52-week range: $3.40 - $17.17.

IBM Reports 4Q'13 Results and Analysts Say Boo!

IBM is not a GDT::Portfolio stock, but IBM reported 4Q'13 results and that means its end-of-year reporting season for 02013.

IBM's 4Q'13 did not meet Wall Street's expectations and right now, in pre-market trading on 02014.01.22, IBM is down 3.6%. IBM closed yesterday (02014.01.21) at $190.09. 52-week range: $172.57 - $215.90.

I found the following interesting.

"We continued to drive strong results across much of our portfolio and again grew earnings per share in 2013. While we made solid progress in businesses that are powering our future, in view of the company’s overall full year results, my senior team and I have recommended that we forgo our personal annual incentive payments for 2013." -- Ginni Rometty, IBM chairman, president and chief executive officer

IBM ended 02013 with "$11.1 billion of cash on hand and generated free cash flow of $15.0 billion excluding Global Financing receivables, down approximately $3.2 billion year over year. The company returned $17.9 billion to shareholders through $4.1 billion in dividends and $13.9 billion of gross share repurchases."

Bought Some More NeuroMetrix (NURO) at $2.50

NeuroMetrix (NURO) announced today (02014.01.21) that "Jiro Nakamura, M.D., Ph.D., has joined its Scientific Advisory Board. Dr. Nakamura is Professor, Division of Diabetes, Department of Internal Medicine, Diabetes Center at the Aichi Medical University School of Medicine in Nagakute, Japan." The NeuroMetrix press release contained the following.

Dr. Nakamura’s position in the Japan medical profession and understanding of local medical practice will be a valuable near-term source of advice and guidance as we move toward the launch of NC-stat DPNCheck in the Japanese market during 2014.

The NeuroMetrix press release stated: "Dr. Nakamura is considered a leader in the field of diabetes research and treatment." I find this believable; consequently, I find it difficult to believe Dr. Nakamura would become associated with a losing company.

NURO closed on 02014.01.17 at $2.61. 52-week range: $1.47 - $4.25.

Sold Some Illumina (ILMN) at 45 $Pi ($141.37)

Illumina (ILMN) spiked to $142.00 this morning (02014.01.21) prompting a sell order to be executed at 45 $Pi (141.37). The sale dropped ILMN from #3 to #4 in the GDT::Portfolio.

Hanger (HGR) Closes Above $40 For the First Time

Hanger (HGR) hit a new 52-week high yesterday (02014.01.15) of $40.54 before closing at $40.45. HGR has been trading since 01992.03.17 and yesterday was the first time it ever closed above $40.

At the start of the year I spent time in a spot where there were a bunch of people my age jogging/running. I was walking, so I kept getting passed by these people. While walking I found myself saying over and over... don't sell anymore Hanger.

Illumina (ILMN) and the $1000 Human Genome

Illumina (ILMN) hit a new 52-week high yesterday (02014.01.14) of $122.35 before closing at $121.51.

Rewind to Stocks::Stuffer posting one 02012.03.29 titled: "Illumina Needs to Say no, nO, NO!". Here's the second paragraph from that posting.

Illumina (ILMN) closed yesterday (02012.03.28) at $49.88. 52-week range: $25.57 - $79.40. Roche's initial offer was $44.50 and their new offer is $51. I don't want sell our ILMN shares at $51 because I think they are worth more than that; therefore, this is potentially bad news because other investors might disagree with my opinion and be happy cashing out at $51. I continue to believe Roche is trying to buy Illumina on the cheap.

Yesterday (02014.01.14) Illumina issued a press release that started with the following.

Illumina, Inc. (ILMN) today broke the ‘sound barrier’ of human genomics by enabling the $1,000 genome. This achievement is made possible by the new HiSeq X Ten Sequencing System. This platform includes dramatic technology breakthroughs that enable researchers to undertake studies of unprecedented scale by providing the throughput to sequence tens of thousands of human whole genomes in a single year in a single lab.

I continue to believe that we have entered into the Age of Genomics.

Nanosphere (NSPH) Has a Wild Friday (1/10/02014)

Nanosphere (NSPH) had a volatile Friday on 02014.01.10. NSPH close at $2.66 on Thursday, 02014.01.09. Prior to the market opening on Friday, Nanosphere issued prelimary 4Q'13 results. NSPH opened Friday at $2.88 (a gap open of 8.3%) and it spiked to an intra-day high of $2.97 (up 11.7%), but it ending up closing at $2.50 (down 6%). Volume was 2.28 million vs. 0.61 million. NSPH 52-week range: $1.72 - $4.49.